VERA Share Price Performance
US$34.25
8.14 (31.18%)
65.8% undervalued intrinsic discount
US$100.00
Fair Value
Price US$34.25
AnalystHighTarget US$100.00
Fair ValueUS$100.00
Share Pricen/a
Seeking Alpha • Sep 15
Vera Therapeutics, Inc. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 17 Fair Values set on narratives written by author
VERA Community Narratives
AN
Fair Value
·Fair Value US$100 65.8% undervalued intrinsic discount
Dual BAFF APRIL Franchise And ORIGIN 3 Data Will Support Long-Term Autoimmune Upside
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
Vera Therapeutics
65.8% undervalued intrinsic discount
New
Dual BAFF APRIL Franchise And ORIGIN 3 Data Will Support Long-Term Autoimmune Upside
View narrativeAN
Published 21 Sep
Trending Discussion
No trending discussion available.
Recently Updated Narratives
AN
Dual BAFF APRIL Franchise And ORIGIN 3 Data Will Support Long-Term Autoimmune Upside
Fair Value: US$100 65.8% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Vera Therapeutics, Inc. Key Details
About VERA
- Founded
- 2016
- Employees
- 361
- CEO
- WebsiteView website
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections that has completed phase 2 clinical trial; and VT-109, a novel BAFF/APRIL dual-inhibitor B cell maturation antigen (BCMA) molecule to treat B cell mediated autoimmune diseases. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.
